Tharimmune Inc (THAR)

Apr 25, 2025

Tharimmune announces board retirements ahead of annual meeting By Investing.com - Investing.com South Africa

Apr 25, 2025

Apr 25, 2025

Press Release Distribution & PR Platform - ACCESS Newswire

Apr 25, 2025

Apr 15, 2025

Tharimmune (THAR) Expands Board with New Appointment | THAR Stoc - GuruFocus

Apr 15, 2025

Apr 15, 2025

Tharimmune Strengthens Strategic Leadership with the Appointment of Vincent LoPriore to its Board of Directors - standard-journal.com

Apr 15, 2025

Apr 15, 2025

Healthcare Investment Expert Managing $150M Portfolio Strengthens Tharimmune's Strategic Leadership - Stock Titan

Apr 15, 2025

Apr 08, 2025

Tharimmune reports data on new biparatopic biologics - BioWorld MedTech

Apr 08, 2025

Apr 07, 2025

THAR stock touches 52-week low at $1.12 amid sharp annual decline By Investing.com - Investing.com South Africa

Apr 07, 2025

Apr 07, 2025

THAR stock touches 52-week low at $1.12 amid sharp annual decline - Investing.com Australia

Apr 07, 2025

Apr 07, 2025

Tharimmune Reports Preclinical Data for Dual-Target Biologics - MarketScreener

Apr 07, 2025

Apr 07, 2025

Tharimmune Announces Positive Data With Novel Biparatopic PD-1/VEGF & Multispecific HER2/HER3 Biologics Leveraging Proprietary Epiclick(TM) Technology - MarketScreener

Apr 07, 2025

Apr 07, 2025

Tharimmune Announces Positive Data with Novel Biparatopic PD-1/VEGF and Multispecific HER2/HER3 Biologics Leveraging Proprietary EpiClick(TM) Technology - Weatherford Democrat

Apr 07, 2025

Apr 07, 2025

Breakthrough Cancer Drug Shows Superior Design: Tharimmune's Dual-Target Biologic Outperforms Competition - Stock Titan

Apr 07, 2025

Apr 05, 2025

Tharimmune receives Nasdaq non-compliance notice - Investing.com Australia

Apr 05, 2025

Apr 05, 2025

Tharimmune receives Nasdaq non-compliance notice By Investing.com - Investing.com Canada

Apr 05, 2025

Apr 03, 2025

Tharimmune, Inc. (NASDAQ:THAR) Short Interest Update - Defense World

Apr 03, 2025

Apr 02, 2025

Virtu Financial LLC Makes New Investment in Tharimmune, Inc. (NASDAQ:THAR) - Defense World

Apr 02, 2025

Mar 31, 2025

THAR stock touches 52-week low at $1.2 amid sharp annual decline By Investing.com - Investing.com South Africa

Mar 31, 2025

Mar 31, 2025

Jayud Global Logistics Ltd (JYD): What Makes The Stock Good? - Marketing Sentinel

Mar 31, 2025

Mar 31, 2025

THAR stock touches 52-week low at $1.2 amid sharp annual decline - Investing.com

Mar 31, 2025

Mar 31, 2025

Tharimmune Says FDA Requires No Additional Trials of TH104 Against Opioid Exposure - MarketScreener

Mar 31, 2025

Mar 31, 2025

FDA greenlights Tharimmune’s drug application pathway - Investing.com India

Mar 31, 2025

Mar 31, 2025

Tharimmune Announces Positive FDA Feedback on NDA Path for TH104 for Prophylaxis of Respiratory and/or CNS Depression for Ultrapotent Opioid Exposure - Weatherford Democrat

Mar 31, 2025

Mar 31, 2025

FDA Fast-Tracks Tharimmune's Revolutionary Opioid Defense Drug: No Clinical Trials Needed - Stock Titan

Mar 31, 2025

Mar 24, 2025

12 Health Care Stocks Moving In Monday's Pre-Market Session - Benzinga

Mar 24, 2025

Mar 24, 2025

Tharimmune Announces Positive Results for Novel Oral Monoclonal Antibody TH023 Targeting Tumor Necrosis Factor-alpha - Weatherford Democrat

Mar 24, 2025

Mar 24, 2025

Game-Changing Oral Alternative to Injectable Antibody Achieves Key Milestone - Stock Titan

Mar 24, 2025

Mar 05, 2025

Tharimmune leverages Epiclick platform to expand pipeline - BioWorld Online

Mar 05, 2025

Mar 04, 2025

Hillstream Biopharma stock hits 52-week low at $1.36 - Investing.com

Mar 04, 2025

Mar 04, 2025

Tharimmune Announces Positive Target Engagement with Novel Biparatopic PD-1/VEGF and Multispecific HER2/HER3 Biologics Leveraging Proprietary EpiClick Technology - Markets Insider

Mar 04, 2025

Mar 04, 2025

Tharimmune unveils novel cancer treatment HS1940 - Investing.com India

Mar 04, 2025

Mar 04, 2025

Tharimmune unveils novel cancer treatment HS1940 By Investing.com - Investing.com South Africa

Mar 04, 2025

Mar 01, 2025

Short Interest in Tharimmune, Inc. (NASDAQ:THAR) Declines By 58.6% - Defense World

Mar 01, 2025

Mar 01, 2025

Short Interest in Virpax Pharmaceuticals, Inc. (NASDAQ:VRPX) Expands By 148.7% - Defense World

Mar 01, 2025

Feb 27, 2025

Tharimmune appoints new CFO following resignation By Investing.com - Investing.com Canada

Feb 27, 2025

Feb 27, 2025

Tharimmune Says Thomas Hess Resigns As CFO -February 27, 2025 at 05:34 pm EST - Marketscreener.com

Feb 27, 2025

Feb 27, 2025

Tharimmune Says Thomas Hess Resigns As CFO - TradingView

Feb 27, 2025

Feb 27, 2025

Tharimmune appoints new CFO following resignation - Investing.com

Feb 27, 2025

Feb 25, 2025

Hillstream Biopharma stock hits 52-week low at $1.83 By Investing.com - Investing.com Canada

Feb 25, 2025

Feb 24, 2025

Hillstream Biopharma stock hits 52-week low at $1.83 - Investing.com

Feb 24, 2025

Feb 23, 2025

Financial Analysis: ObsEva (NASDAQ:OBSV) & Tharimmune (NASDAQ:THAR) - Defense World

Feb 23, 2025

Feb 22, 2025

Comparing Tharimmune (NASDAQ:THAR) and Phio Pharmaceuticals (NASDAQ:PHIO) - Defense World

Feb 22, 2025

Feb 19, 2025

Tharimmune (NASDAQ:THAR) and Cara Therapeutics (NASDAQ:CARA) Head-To-Head Review - Armenian Reporter

Feb 19, 2025

Feb 17, 2025

Comparing Cara Therapeutics (NASDAQ:CARA) & Tharimmune (NASDAQ:THAR) - Defense World

Feb 17, 2025

Feb 13, 2025

Larchmont broker accused of years-long insider trading scheme - Westfair Communications

Feb 13, 2025

Feb 07, 2025

Tharimmune (NASDAQ:THAR) Trading 3% Higher – Should You Buy? - Defense World

Feb 07, 2025